Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis.
Idiopathic pulmonary fibrosis
Patient-reported outcome
Quality of life
Rare diseases
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
01 Mar 2019
01 Mar 2019
Historique:
received:
12
10
2018
accepted:
20
02
2019
entrez:
3
3
2019
pubmed:
3
3
2019
medline:
25
6
2019
Statut:
epublish
Résumé
Idiopathic pulmonary fibrosis (IPF) is a rare disease with a median survival of 3-5 years after diagnosis with limited treatment options. The aim of this study is to assess the psychometric characteristics of the Short Form 36 Health Status Questionnaire (SF-36) in IPF and to provide disease specific minimally important differences (MID). Data source was the European IPF Registry (eurIPFreg). The psychometric properties of the SF-36 version 2 were evaluated based on objective clinical measures as well as subjective perception. We analysed acceptance, feasibility, discrimination ability, construct and criterion validity, responsiveness and test-retest-reliability. MIDs were estimated via distribution and anchor-based approaches. The study population included 258 individuals (73.3% male; mean age 67.3 years, SD 10.7). Of them 75.2% (194 individuals) had no missing item. The distribution of several items was skewed, although floor effect was acceptable. Physical component score (PCS) correlated significantly and moderately with several anchors, whereas the correlations of mental component score (MCS) and anchors were only small. The tests showed mainly significant lower HRQL in individuals with long-term oxygen therapy. Analyses in stable individuals did not show significant changes of HRQL except for one dimension and anchor. Individuals with relevant changes of the health status based on the anchors had significant changes in all SF-36 dimensions and summary scales except for the dimension PAIN. PCS and MCS had mean MIDs of five and six, respectively. Mean MIDs of the dimensions ranged from seven to 21. It seems that the SF-36 is a valid instrument to measure HRQL in IPF and so can be used in RCTs or individual monitoring of disease. Nevertheless, the additional evaluation of longitudinal aspects and MIDs can be recommended to further analyse these factors. Our findings have a great potential impact on the evaluation of IPF patients. The eurIPFreg and eurIPFbank are listed in https://clinicaltrials.gov ( NCT02951416 ).
Sections du résumé
BACKGROUND
BACKGROUND
Idiopathic pulmonary fibrosis (IPF) is a rare disease with a median survival of 3-5 years after diagnosis with limited treatment options. The aim of this study is to assess the psychometric characteristics of the Short Form 36 Health Status Questionnaire (SF-36) in IPF and to provide disease specific minimally important differences (MID).
METHODS
METHODS
Data source was the European IPF Registry (eurIPFreg). The psychometric properties of the SF-36 version 2 were evaluated based on objective clinical measures as well as subjective perception. We analysed acceptance, feasibility, discrimination ability, construct and criterion validity, responsiveness and test-retest-reliability. MIDs were estimated via distribution and anchor-based approaches.
RESULTS
RESULTS
The study population included 258 individuals (73.3% male; mean age 67.3 years, SD 10.7). Of them 75.2% (194 individuals) had no missing item. The distribution of several items was skewed, although floor effect was acceptable. Physical component score (PCS) correlated significantly and moderately with several anchors, whereas the correlations of mental component score (MCS) and anchors were only small. The tests showed mainly significant lower HRQL in individuals with long-term oxygen therapy. Analyses in stable individuals did not show significant changes of HRQL except for one dimension and anchor. Individuals with relevant changes of the health status based on the anchors had significant changes in all SF-36 dimensions and summary scales except for the dimension PAIN. PCS and MCS had mean MIDs of five and six, respectively. Mean MIDs of the dimensions ranged from seven to 21.
CONCLUSION
CONCLUSIONS
It seems that the SF-36 is a valid instrument to measure HRQL in IPF and so can be used in RCTs or individual monitoring of disease. Nevertheless, the additional evaluation of longitudinal aspects and MIDs can be recommended to further analyse these factors. Our findings have a great potential impact on the evaluation of IPF patients.
TRIAL REGISTRATION
BACKGROUND
The eurIPFreg and eurIPFbank are listed in https://clinicaltrials.gov ( NCT02951416 ).
Identifiants
pubmed: 30823880
doi: 10.1186/s12931-019-1010-5
pii: 10.1186/s12931-019-1010-5
pmc: PMC6397447
doi:
Banques de données
ClinicalTrials.gov
['NCT02951416']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Références
Chest. 1999 Nov;116(5):1175-82
pubmed: 10559073
Mayo Clin Proc. 2002 Apr;77(4):371-83
pubmed: 11936935
Br Med J. 1976 Apr 3;1(6013):822-3
pubmed: 1260350
Eur Respir J. 2003 Feb;21(2):267-72
pubmed: 12608440
Med Care. 2003 May;41(5):582-92
pubmed: 12719681
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
J Physiol Pharmacol. 2005 Sep;56 Suppl 4:99-105
pubmed: 16204782
Am Heart J. 2006 Apr;151(4):837-43
pubmed: 16569543
Health Qual Life Outcomes. 2006 Sep 27;4:70
pubmed: 17005038
Braz J Med Biol Res. 2007 Feb;40(2):179-87
pubmed: 17273654
Intern Med. 2007;46(18):1533-42
pubmed: 17878639
Am J Respir Crit Care Med. 2008 Jan 1;177(1):75-81
pubmed: 17901413
J Clin Epidemiol. 2008 Feb;61(2):102-9
pubmed: 18177782
Am J Respir Crit Care Med. 2008 Nov 1;178(9):948-55
pubmed: 18669816
Thorax. 2008 Sep;63 Suppl 5:v1-58
pubmed: 18757459
Respir Med. 2009 Oct;103(10):1430-5
pubmed: 19477109
Respir Med. 2010 Feb;104(2):296-304
pubmed: 19815403
Am J Respir Crit Care Med. 2011 Feb 15;183(4):431-40
pubmed: 20935110
Am J Respir Crit Care Med. 2011 May 1;183(9):1231-7
pubmed: 21131468
Eur Respir J. 2011 Apr;37(4):747-8
pubmed: 21454892
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Am J Respir Crit Care Med. 2011 Jul 1;184(1):92-9
pubmed: 21474646
Am J Respir Crit Care Med. 2012 May 15;185(10):1044-8
pubmed: 22505745
Chest. 2012 Aug;142(2):291-297
pubmed: 22871754
Pneumologie. 2013 Feb;67(2):81-111
pubmed: 23325398
Qual Life Res. 2014 Feb;23(1):1-4
pubmed: 23722635
Chest. 2013 Jun;143(6):1699-1708
pubmed: 23732584
Curr Opin Pulm Med. 2013 Sep;19(5):474-9
pubmed: 23851327
Expert Rev Respir Med. 2014 Apr;8(2):173-8
pubmed: 24450476
Respir Med. 2015 Jul;109(7):914-22
pubmed: 25956020
Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19
pubmed: 26177183
BMC Med. 2015 Sep 24;13:240
pubmed: 26399318
BMJ Open. 2015 Oct 01;5(10):e007953
pubmed: 26428330
Respiration. 2016;91(6):497-502
pubmed: 27240427
Gesundheitswesen. 2018 Feb;80(2):132-143
pubmed: 27846666
Eur Respir J. 2017 Jan 18;49(1):
pubmed: 28100551
Pneumologie. 2018 Feb;72(2):155-168
pubmed: 29341047
Respir Res. 2018 Jul 28;19(1):141
pubmed: 30055613
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Chest. 1988 Mar;93(3):580-6
pubmed: 3342669
Thorax. 1979 Apr;34(2):254-8
pubmed: 483195
Chest. 1984 Jun;85(6):751-8
pubmed: 6723384
Br Med J (Clin Res Ed). 1982 May 29;284(6329):1607-8
pubmed: 6805625
Age Ageing. 1995 Mar;24(2):120-5
pubmed: 7793333
J Epidemiol Community Health. 1998 May;52(5):324-8
pubmed: 9764284